No robust reduction of infarct size and no-reflow by metoprolol pretreatment in adult Gottingen minipigs

Whereas prior experiments in juvenile pigs had reported infarct size reduction by intravenous metoprolol early during myocardial ischaemia, two major clinical trials in patients with reperfused acute myocardial infarction were equivocal. We, therefore, went back and tested the translational robustness of infarct size reduction by metoprolol in minipigs. Using a power analysis-based prospective design, we pretreated 20 anaesthetised adult Gottingen minipigs with 1 mg kg(-1) metoprolol or placebo and subjected them to 60-min coronary occlusion and 180-min reperfusion. Primary endpoint was infarct size (triphenyl tetrazolium chloride staining) as a fraction of area at risk; no-reflow area (thioflavin-S staining) was a secondary endpoint. There was no significant reduction in infarct size (46 +/- 8% of area at risk with metoprolol vs. 42 +/- 8% with placebo) or area of no-reflow (19 +/- 21% of infarct size with metoprolol vs. 15 +/- 23% with placebo). However, the inverse relationship between infarct size and ischaemic regional myocardial blood flow was modestly, but significantly shifted downwards with metoprolol, whereas ischaemic blood flow tended to be reduced by metoprolol. With an additional dose of 1 mg kg(-1) metoprolol after 30-min ischaemia in 4 additional pigs, infarct size was also not reduced (54 +/- 9% vs. 46 +/- 8% in 3 contemporary placebo, n.s.), and area of no-reflow tended to be increased (59 +/- 20% vs. 29 +/- 12%, n.s.).Infarct size reduction by metoprolol in pigs is not robust, and this result reflects the equivocal clinical trials. The lack of infarct size reduction may be the result of opposite effects of reduced infarct size at any given blood flow and reduced blood flow, possibly through unopposed alpha-adrenergic coronary vasoconstriction.